Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Supraciliary microstent implantation for lowering IOP in glaucoma patients undergoing cataract surgery: randomized, controlled 3-year results from a single center

Poster Details

First Author: S. Vold UNITED STATES

Co Author(s):                        

Abstract Details

Purpose:

To evaluate 3-year safety and efficacy of supraciliary microstent implantation combined with cataract surgery from a single center.

Setting:

Multi-site international clinical study

Methods:

Patients underwent glaucoma medication washout before the unmedicated baseline evaluation. Patients were randomized to cataract surgery alone (Control) or cataract surgery plus implantation with CyPass (Treatment). Primary efficacy outcome was proportion of eyes with unmedicated diurnal IOP reduction ≥20% at 24 months (M) vs unmedicated baseline IOP

Results:

We retrospectively report on patients who completed the 36M visit in the Control (N=12) and Treatment (N=36) arms. At the 36M visit, the proportion of patients with IOP ≤18 mmHg without medications was 25% for controls vs 61% for the treatment group. Medication reduction was reduced in both groups. Control group patients decreased from 1.3 meds at baseline to 0.9 at 36M; treatment patients decreased from 1.5 meds at baseline to 0.3 meds at 36M. The safety profile between the two groups was similar, and there were no major sight-threatening adverse events.

Conclusions:

Cataract surgery alone did not decrease IOP or IOP-lowering medications required over 36M; however, implantation of CyPass stent significantly decreased IOP from baseline sustained through 36M with few AEs related to stent implantation. Patients maintained their low IOP sustained through 3 years of follow-up.

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented, One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing